Paris and Atlanta, November 6, 2007 – Biospace med, developer of the EOS ultra low dose 2D|3D Xray imager*, announced the arrival of Joe Sardano and Peter Cardle to its global sales team. The new hires increase the company's presence in the international healthcare market and prepare it for entry into the North American marketplace.
Joe Sardano, Senior Vice President, Americas, has extensive background in the healthcare industry. Sardano's experience includes sales, marketing, service and sales management with several major imaging companies including GE Medical Systems, Siemens and Toshiba. He successfully managed the global commercialization and revenue growth of CTI Molecular Imaging from 2002-2005 prior to its acquisition by Siemens.
"Mr. Sardano's background in the healthcare industry, and more specifically the diagnostic imaging marketplace, adds a tremendous amount of experience to the already impressive Biospace med team," says Marie Meynadier, CEO of Biospace med. "His track record of revenue growth and market expansion within companies has made him a sought-after healthcare professional, and we are pleased he has joined our company."
Another notable addition to Biospace med's global sales team is Peter Cardle, European Sales Vice President. Cardle has over 25 years of medical imaging experience within GE Healthcare, as well as several companies such as Sterling, eRAD and Fischer. Cardle's breadth of experience includes roles ranging from service and sales to president within the respective companies.
"Mr. Cardle solidifies our intent on successfully transitioning into a global company," Meynadier explains. "Our international leadership team brings strong management skills that fully prepare us for entering the U.S. market."
Sardano and Cardle were added to the management team to help grow sales globally, as well as successfully introduce EOS to the North American marketplace.
"The Nobel prize-winning technology and expertise of a world-renowned pediatric orthopedic surgeon behind EOS make it an innovative Xray imager," adds Meynadier. "Now we have one of the best management teams in the world to promote it, and help us lead the global market with exceptional Xray technology."
About the EOS system
The EOS ultra-low-dose 2D|3D Xray imager is based on patented detector technology for which Georges Charpak received the Nobel Prize in Physics. EOS 2D|3D technology is part of a total solution to orthopedic imaging, allowing images to be obtained with a low dose of radiation. It is capable of long length digital imaging, permitting full-body, uninterrupted digital imaging with a single scan.
EOS differs in several other respects from traditional film, digital Xray or CT. Its use of slot scanning technology eliminates vertical distortion that is common with traditional Xray systems. In addition, EOS enables long length digital imaging without the need for digital stitching – all at a reduced dose. The simultaneous bi-plane image acquisition (front and side images acquired at the same time) eliminates the need for taking a second view and can save time.
While the medical imaging industry has made an extensive effort to lower the dosage between .1 and .5 times, the technology of EOS allows the dosage to be five to 10 times less than other conventional or digital Xray equipment. With these new advances in imaging, biospace med systems may eliminate the need for very high dose CT scans – especially for younger patients such as those afflicted with scoliosis while improving the diagnosis and treatment of many spinal and bone diseases. About 900,000 patients, mostly teenagers, have scoliosis in the U.S. and require regularly scheduled Xray monitoring of their disease.
About Biospace med
Biospace med was founded on a unique partnership between a Nobel Prize- winning physicist and a team of biomedical engineers, orthopedic surgeons, and radiologists who have developed a complete orthopedic imaging solution. The company's lead product, EOS ultra low dose 2D|3D Xray imager, allows full-body imaging of patients in a weight-bearing position that will enable global assessment of balance and posture. EOS is a total solution in orthopedic imaging now available in the U.S since receiving FDA 510k clearance. An advanced workstation*, designed to generate a 3D skeletal image from the two planar images, is under development. The company has corporate headquarters in Paris and Atlanta with an office in Montreal, and is targeting a $2 billion orthopedic imaging marketplace. Biospace med is venture-backed by a pool of investors led by Edmond de Rothschild Investment Partners. Learn more at http://www.biospacemed.com.
*EOS 3D is currently commercially available in Europe and Canada only, and is not part of the current FDA clearance.
